These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 24124872)

  • 1. New developments in cancer vaccines.
    Buonaguro L; Aurisicchio L; Buonaguro FM; Ciliberto G
    Expert Rev Vaccines; 2013 Oct; 12(10):1109-10. PubMed ID: 24124872
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer vaccines in the new era of cancer immunotherapy.
    Knutson KL; Mittendorf EA
    Vaccine; 2015 Dec; 33(51):7376. PubMed ID: 26432907
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer.
    Berzofsky JA; Wood LV; Terabe M
    Expert Rev Vaccines; 2013 Oct; 12(10):1115-8. PubMed ID: 24124874
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic cancer vaccines: a long and winding road to success.
    Baxevanis CN; Papamichail M; Perez SA
    Expert Rev Vaccines; 2014 Jan; 13(1):131-44. PubMed ID: 24224539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing immunogenicity of cancer vaccines to improve their clinical outcome.
    Parmiani G; Cimminiello C; Maccalli C
    Expert Rev Vaccines; 2013 Oct; 12(10):1111-3. PubMed ID: 24124873
    [No Abstract]   [Full Text] [Related]  

  • 6. A power surge for cancer immunotherapy: antibodies, vaccines, and engineered T cells fuel new optimism.
    Nelson B
    Cancer Cytopathol; 2014 Jan; 122(1):1-2. PubMed ID: 24424750
    [No Abstract]   [Full Text] [Related]  

  • 7. Overview of the cancer vaccine field: are we moving forward?
    Kudrin A; Hanna MG
    Hum Vaccin Immunother; 2012 Aug; 8(8):1135-40. PubMed ID: 22854670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.
    Bot A; Marincola F; Smith KA
    Expert Rev Vaccines; 2013 Oct; 12(10):1219-34. PubMed ID: 24099049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the development of an autologous heat shock protein based anti-tumor vaccine.
    Reitsma DJ; Combest AJ
    Hum Vaccin Immunother; 2012 Aug; 8(8):1152-5. PubMed ID: 22854658
    [No Abstract]   [Full Text] [Related]  

  • 10. Personalized cancer neoantigen vaccines come of age.
    Chu Y; Liu Q; Wei J; Liu B
    Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized cancer vaccines.
    Jain KK
    Expert Opin Biol Ther; 2010 Dec; 10(12):1637-47. PubMed ID: 20979567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comments on therapeutic cancer vaccines.
    Vonka V
    Immunotherapy; 2012 Feb; 4(2):133-5. PubMed ID: 22339454
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytotoxic T lymphocytes: the future of cancer stem cell eradication?
    Saijo H; Hirohashi Y; Torigoe T; Kochin V; Takahashi H; Sato N
    Immunotherapy; 2013 Jun; 5(6):549-51. PubMed ID: 23725275
    [No Abstract]   [Full Text] [Related]  

  • 14. [New era of tumor immunotherapy].
    Yoshitake Y; Nakatsura T; Nishimura Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
    [No Abstract]   [Full Text] [Related]  

  • 15. Reconsidering the paradigm of cancer immunotherapy by computationally aided real-time personalization.
    Kogan Y; Halevi-Tobias K; Elishmereni M; Vuk-Pavlović S; Agur Z
    Cancer Res; 2012 May; 72(9):2218-27. PubMed ID: 22422938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy.
    Croix BS
    Cytotherapy; 2007; 9(1):1-3. PubMed ID: 17354097
    [No Abstract]   [Full Text] [Related]  

  • 18. MUC1 as a target antigen for cancer immunotherapy.
    Acres B; Limacher JM
    Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Q&A: Evidence presenter. Interview by Marian Turner.
    Palucka K
    Nature; 2013 Dec; 504(7480):S9. PubMed ID: 24352364
    [No Abstract]   [Full Text] [Related]  

  • 20. Improving the efficacy of cancer immunotherapy.
    Copier J; Dalgleish AG; Britten CM; Finke LH; Gaudernack G; Gnjatic S; Kallen K; Kiessling R; Schuessler-Lenz M; Singh H; Talmadge J; Zwierzina H; Håkansson L
    Eur J Cancer; 2009 May; 45(8):1424-31. PubMed ID: 19167214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.